Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acne mRNA vaccine
- Development stage
- Phase 2
- Lead developer
- Sanofi Pasteur
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The acne mRNA vaccine is a first-in-class investigational therapeutic mRNA-based vaccine designed to treat moderate to severe acne vulgaris. It targets antigens from pathogenic strains of *Cutibacterium acnes* (C. acnes), the bacterium implicated in the development of inflammatory and non-inflammatory lesions in clinical disease. The mechanism involves encoding specific C. acnes antigens via messenger RNA, delivered intramuscularly, to elicit an immune response that neutralizes pathogenic bacterial factors while sparing commensal skin flora. This approach aims for a more precise and less disruptive treatment than current therapies by reducing inflammation and lesion count without broad-spectrum antimicrobial effects[2][8]. The candidate is currently being developed by Sanofi Pasteur following its acquisition of Origimm Bio GmbH, which initially pioneered the antigen discovery platform[6][8]. The product is in Phase 1/2 clinical trials for adults with moderate to severe acne[1][5][8].
- Other names
- acne vaccineCutibacterium acnes mRNA vaccine
02
Targets
Cutibacterium acnes cell wall and associated proteins
Beyond the preview
Go deeper on Acne mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acne mRNA vaccine.